NuraLogix has developed an artificial intelligence (AI) model that can predict a person’s risk of having fatty liver disease (FLD) by using facial blood patterns.

The technology is part of the company’s contactless health platform, which uses patented Transdermal Optical Imaging (TOI) technology to extract facial blood flow information and combine it with powerful AI data models developed from more than 40,000 patients with multiple health conditions. NuraLogix’s Anura contactless health platform is already able to take over 30 medical-grade health vitals using any video-enabled device, and the new capability adds to its existing capabilities that include T2 diabetes risk assessments, cardiovascular disease risks, depression health risk and hypertension risk.

Article written by  Cora Lydon



Digital Health